Use of a Diabetes Self-Management Application in Combination with a 4 mm Pen Needle and Its Impact on Glycemic Variability and Patient-Reported Outcomes in People with Type 2 Diabetes Using Basal-Bolus Insulin Therapy
Clinical Diabetology
; 11(3):156-164, 2022.
Article
in English
| EMBASE | ID: covidwho-1988338
ABSTRACT
Background:
Studies of mobile diabetes applications (apps) have demonstrated improvements in glycemia, and patient-reported outcomes (PROs). In addition, shift to shorter pen needles (PN) and guidance on proper injection techniques have shown the potential for reduced glycemic variability. The purpose is to determine the impact of using a diabetes mobile app plus a novel 4 mm PN on PROs and glycemic outcomes in type 2 diabetes mellitus (T2DM) for multiple daily injection (MDI) insulin users. Materials andmethods:
In this 8-week prospective, parallel-group, randomized controlled trial, subjects either received (11) intervention (BD Diabetes Care [DC] App + BD Nano TM 2nd Gen PN) or control therapy. Controls used their current PN and did not use diabetes apps.Results:
Fifty-eight subjects were randomized. Fifty-seven completed the study (intervention n = 27, control n = 30). At study end, there were no significant differences in PROs between groups, except improved medication adherence (ARMS-D) in controls. From flash glucose monitoring (fGM) data, there were no significant differences in most glycemic measures between groups except for a trend for improved glycemic variability [mean amplitude of the glycemic excursions (MAGE)] in the Intervention (p = 0.06). Controls had significantly reduced time spent in hypoglycemia but had 2 to 3-fold higher incidence at baseline. In general, Intervention subjects reported satisfaction with both the app and PN.Conclusions:
This is the first BD DC App study, in combination with BD Nano TM 2nd Gen PN, to assess glycemic outcomes. This combination intervention shows promising results for reduced glycemic variability and the potential to positively impact self-management.
blood glucose meter; glucose sensor; mobile health application; needle; hemoglobin A1c; insulin; nanochain; adult; article; blood glucose monitoring; clinical assessment; clinical trial; controlled study; coronavirus disease 2019; diabetes mellitus; drug therapy; female; human; hypoglycemia; incidence; insulin treatment; major clinical study; male; medication compliance; middle aged; mobile application; non insulin dependent diabetes mellitus; outcome assessment; parallel design; patient-reported outcome; prospective study; randomized controlled trial; satisfaction; self care
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Experimental Studies
Language:
English
Journal:
Clinical Diabetology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS